Which has stronger valuation & earnings, INAB or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is INAB or TIL more profitable?

Instil Bio's return on equity of -39.76% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Instil Bio N/A -39.76% -22.38%

Do analysts rate INAB or IZTC?

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe IN8bio is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, INAB or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is INAB or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Invizyne Technologies N/A N/A N/A

Do analysts prefer ABVC or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ABVC or INAB more profitable?

ABVC BioPharma's return on equity of -62.46% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% IN8bio N/A -96.39% -80.18%

Is INAB or MREO more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Mereo BioPharma Group N/A -81.28% -70.45%

Does the media refer more to INAB or MREO?

In the previous week, Mereo BioPharma Group had 1 more articles in the media than IN8bio. MarketBeat recorded 2 mentions for Mereo BioPharma Group and 1 mentions for IN8bio. Mereo BioPharma Group's average media sentiment score of 0.49 beat IN8bio's score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INAB or TCRT?

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, INAB or TCRT?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is INAB or TCRT more profitable?

IN8bio's return on equity of -96.39% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Alaunos Therapeutics N/A -165.94% -123.50%

Does the media prefer INAB or TCRT?

In the previous week, IN8bio and IN8bio both had 1 articles in the media. IN8bio's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alaunos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

IN8bio (INAB) Competitors

$1.38 -0.01 (-0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 -0.01 (-1.09%)

As of 04:59 PM Eastern

Compare

INAB vs. TIL, IZTC, ABVC, MREO, and TCRT

Should you buy IN8bio stock or one of its competitors? MarketBeat compares IN8bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IN8bio include Instil Bio (TIL), Invizyne Technologies (IZTC), ABVC BioPharma (ABVC), Mereo BioPharma Group (MREO), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry.

How does IN8bio compare to Instil Bio?

IN8bio (NASDAQ:INAB) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, IN8bio had 1 more articles in the media than Instil Bio. MarketBeat recorded 1 mentions for IN8bio and 0 mentions for Instil Bio. IN8bio's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
IN8bio	Neutral
Instil Bio	Neutral

Instil Bio's return on equity of -39.76% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Instil Bio	N/A	-39.76%	-22.38%

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Instil Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

IN8bio has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 189.86%. Instil Bio has a consensus target price of $66.00, indicating a potential upside of 748.33%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

IN8bio beats Instil Bio on 7 of the 12 factors compared between the two stocks.

How does IN8bio compare to Invizyne Technologies?

IN8bio (NASDAQ:INAB) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe IN8bio is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, IN8bio had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for IN8bio and 0 mentions for Invizyne Technologies. IN8bio's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company	Overall Sentiment
IN8bio	Neutral
Invizyne Technologies	Neutral

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Invizyne Technologies	N/A	N/A	N/A

Summary

IN8bio beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks.

How does IN8bio compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

ABVC BioPharma's return on equity of -62.46% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
IN8bio	N/A	-96.39%	-80.18%

ABVC BioPharma has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, IN8bio had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 1 mentions for IN8bio and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 equaled IN8bio'saverage media sentiment score.

Company	Overall Sentiment
ABVC BioPharma	Neutral
IN8bio	Neutral

ABVC BioPharma has higher revenue and earnings than IN8bio. ABVC BioPharma is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	102.98	-$7.91M	-$0.40	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ABVC BioPharma beats IN8bio on 7 of the 13 factors compared between the two stocks.

How does IN8bio compare to Mereo BioPharma Group?

IN8bio (NASDAQ:INAB) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Mereo BioPharma Group had 1 more articles in the media than IN8bio. MarketBeat recorded 2 mentions for Mereo BioPharma Group and 1 mentions for IN8bio. Mereo BioPharma Group's average media sentiment score of 0.49 beat IN8bio's score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mereo BioPharma Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.1% of IN8bio shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IN8bio has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Mereo BioPharma Group's return on equity of -81.28% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

IN8bio has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Mereo BioPharma Group	$500K	100.88	-$41.88M	-$0.05	N/A

IN8bio presently has a consensus target price of $4.00, suggesting a potential upside of 189.86%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 928.48%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Mereo BioPharma Group beats IN8bio on 10 of the 14 factors compared between the two stocks.

How does IN8bio compare to Alaunos Therapeutics?

IN8bio (NASDAQ:INAB) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

IN8bio's return on equity of -96.39% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

In the previous week, IN8bio and IN8bio both had 1 articles in the media. IN8bio's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.1% of IN8bio shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IN8bio has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the broader market.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Summary

IN8bio beats Alaunos Therapeutics on 8 of the 11 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.69M	$3.80B	$6.99B	$12.46B
Dividend Yield	N/A	2.17%	2.67%	7.39%
P/E Ratio	-0.53	21.49	27.17	24.24
Price / Sales	N/A	328.43	534.05	96.53
Price / Cash	N/A	148.60	49.24	56.96
Price / Book	0.49	8.47	10.83	6.38
Net Income	-$19.44M	$23.73M	$3.56B	$331.19M
7 Day Performance	-2.82%	1.50%	0.81%	-1.84%
1 Month Performance	-4.17%	12.00%	5.61%	0.85%
1 Year Performance	-37.27%	62.03%	32.58%	22.18%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	3.429 of 5 stars	$1.38 -0.7%	$4.00 +189.9%	-33.8%	$13.69M	N/A	N/A	20	News Coverage
TIL Instil Bio	1.3131 of 5 stars	$7.82 +1.3%	$66.00 +743.6%	-67.2%	$53.05M	N/A	N/A	410
IZTC Invizyne Technologies	N/A	$8.48 -0.2%	N/A	-17.9%	$53.02M	N/A	N/A	29
ABVC ABVC BioPharma	0.2535 of 5 stars	$2.01 +5.5%	N/A	-49.4%	$52.13M	$510K	N/A	30	High Trading Volume
MREO Mereo BioPharma Group	3.3536 of 5 stars	$0.32 +0.8%	$3.25 +918.8%	-88.5%	$50.92M	$500K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. TIL, IZTC, ABVC, MREO, and TCRT

How does IN8bio compare to Instil Bio?

Summary

How does IN8bio compare to Invizyne Technologies?

Summary

How does IN8bio compare to ABVC BioPharma?

Summary

How does IN8bio compare to Mereo BioPharma Group?

Summary

How does IN8bio compare to Alaunos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. TIL, IZTC, ABVC, MREO, and TCRT

How does IN8bio compare to Instil Bio?

Does the media refer more to INAB or TIL?

Is INAB or TIL more profitable?

Do insiders & institutionals believe in INAB or TIL?

Which has stronger valuation & earnings, INAB or TIL?

Which has more volatility and risk, INAB or TIL?

Do analysts prefer INAB or TIL?

Summary

How does IN8bio compare to Invizyne Technologies?

Do institutionals & insiders have more ownership in INAB or IZTC?

Do analysts rate INAB or IZTC?

Which has better earnings and valuation, INAB or IZTC?

Does the media favor INAB or IZTC?

Is INAB or IZTC more profitable?

Summary

How does IN8bio compare to ABVC BioPharma?

Is ABVC or INAB more profitable?

Which has more risk & volatility, ABVC or INAB?

Do institutionals and insiders have more ownership in ABVC or INAB?

Does the media refer more to ABVC or INAB?

Which has higher valuation & earnings, ABVC or INAB?

Do analysts prefer ABVC or INAB?

Summary

How does IN8bio compare to Mereo BioPharma Group?

Does the media refer more to INAB or MREO?

Do institutionals & insiders believe in INAB or MREO?

Which has more risk & volatility, INAB or MREO?

Is INAB or MREO more profitable?

Which has stronger valuation and earnings, INAB or MREO?

Do analysts recommend INAB or MREO?

Summary

How does IN8bio compare to Alaunos Therapeutics?

Is INAB or TCRT more profitable?

Does the media prefer INAB or TCRT?

Do institutionals & insiders believe in INAB or TCRT?

Do analysts rate INAB or TCRT?

Which has more volatility & risk, INAB or TCRT?

Which has stronger valuation and earnings, INAB or TCRT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools